突发！重组终止

Core Viewpoint - Newnow has decided to terminate its major asset restructuring plan after 15 months, citing changes in the pharmaceutical industry and capital market conditions since the initial planning [1][3]. Group 1: Restructuring Details - The original restructuring plan involved acquiring 100% of Shiyao Baike for a total price of 7.6 billion yuan, with 6.84 billion yuan in stock and 760 million yuan in cash [3]. - The target company, Shiyao Baike, reported a revenue of 2.316 billion yuan and a net profit of 785 million yuan in 2023, but is expected to see a decline in revenue and net profit in the first half of 2024 due to price impacts from provincial alliance procurement [3][6]. - Newnow received an inquiry letter from the Shenzhen Stock Exchange during the restructuring process, requiring disclosure of key operational and financial information [3]. Group 2: Market Reaction - Following the announcement of the restructuring termination, Newnow's stock price dropped over 16% in early trading on April 29, eventually closing down 3.63% at 39.6 yuan per share, with a total market capitalization of 55.6 billion yuan [5]. Group 3: Financial Performance - Newnow's financial performance in 2024 showed significant pressure, with revenues of 1.981 billion yuan, a year-on-year decrease of 21.98%, and a net profit attributable to shareholders of 53.73 million yuan, down 87.63% [6].